Pfizer reported additional data on PAXLOVID supporting New Drug Application submission to U.S. FDA
On Jun. 14 2022, Pfizer reported data from the Phase 2/3 EPIC-SR (Evaluation of Protease Inhibition for COVID-19…
-
-
Moderna announced Omicron-containing bivalent booster candidate mRNA-1273.214 demonstrated superior antibody response against Omicron
On Jun. 8, 2022, Moderna announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing…
-
Zoetis Announces Agreement to Acquire Basepaws, an Innovative Leader in Petcare Genetics
On Jun. 7, 2022, Zoetis announced an agreement to acquire Basepaws, a privately held petcare genetics company, which…
-
Merck and Ridgeback announcd data for investigational LAGEVRIO (molnupiravir) from Phase 3 MOVe-OUT study
On Jun. 7, 2022, Merck and Ridgeback Biotherapeutics announced the Annals of Internal Medicine had published additional data…
-
Veru submitted EUA to U.S. FDA for Sabizabulin, its anti-Inflammatory drug candidate for hospitalized COVID-19 patients
On Jun. 7, 2022, Veru, a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral…
-
Common drug-resistant superbug developed fast resistance to ‘last resort’ antibiotic
On Jun. 7, 2022, the University of Oxford reported research has found that Pseudomonas bacterium develops resistance much…
-
Pfizer announced $120 million investment to produce COVID-19 oral treatment in the U.S.
On Jun. 6, 2022, Pfizer further strengthened its commitment to United States manufacturing with a $120 million investment…
-
Moderna and the European Commission agreed on amendment to COVID-19 vaccine supply agreement
On Jun. 2, 2022, The European Commission and the vaccine developer Moderna announced they have reached an agreement…
-
Immune modulator drugs improved survival for people hospitalized with COVID-19
On Jun. 2, 2022, the U.S. National Institutes of Health (NIH) announced that a large randomized, placebo-controlled clinical…
-
Biotechnology | Disease | Medicine | NIH | Ophthalmogy | Therapeutics
NIH study confirmed benefit of supplements for slowing age-related macular degeneration
On Jun. 2, 2022, the National Institutes of Health (NIH) reported that the Age-Related Eye Disease Studies (AREDS…
-
Ultima Genomics delivered the $100 genome
On May 31, 2022, Ultima Genomics emerged from stealth business mode with a new high-throughput, low-cost sequencing platform…
-
Moderna and Takeda announced plans to transfer Marketing Authorization for Spikevax(TM) COVID-19 vaccine in Japan
On May 31, 2022, Moderna and Takeda announced the transfer of the marketing authorization for Moderna’s COVID-19 vaccine…
-
Wake Forest CCSG cut from 5 years to 3 as center changes leadership, administrative structure
May 27, 2022, the National Cancer Institute (NCI) truncated the just-renewed five-year Cancer Center Support Grant held by…
-
Pfizer-BioNTech COVID-19 vaccine demonstrated strong immune response in children 6 months to under 5 years of age following third dose
On May 25, 2022, Pfizer and BioNTech announced topline safety, immunogenicity and vaccine efficacy data from a Phase…
-
Artificial Intelligence | Biotechnology | Genomics | Infectious Disease | Medicine | Neurology | NIH | Non-Profit Research | Oncology | Pharmaceutical | Therapeutics
The Advanced Research Projects Agency for Health (ARPA-H) was established
On May 25, 2022, the Health and Human Services agency (HHS) announced the formal establishment of the Advanced…
-
Depression, loneliness associated with increased hospitalization risk after COVID-19
On May 19, 2022, the U.S. National Institutes of Health (NIH) announced that people who reported in a…
-
NIH announced antiviral drug development awards
On May 18, 2022, the U.S. National Institutes of Health announced it had awarded approximately $577 million to…
-
Study found ‘natural immunity’ from Omicron weak and limited
On May 18, 2022, researchers at Gladstone Institutes and UC San Francisco (UCSF) reported that unvaccinated people, infection…
-
Cepheid received Emergency Use Authorization for Xpert Xpress CoV-2 plus
On May 12, 2022, Cepheid announced it had received Emergency Use Authorization from the U.S. Food & Drug…
-
KPWHRI report supported value of COVID-19 drugs
On May 11, 2022, Kaiser Permanente Washington Health Research Institute reported that new treatments for people at high…
-
Sorrento announced full enrollment of phase I study of intranasal STI-9199 (COVISHIELD) against Omicron BA.2 and all variants of concern
On May 2, 2022, Sorrento announced its Phase I study of intranasal STI-919 OVISHIELDTM) had been fully enrolled…
-
WHO reported Ebola virus disease in Democratic Republic of the Congo
On Apr. 28, 2022, the Ministry of Health of the Democratic Republic of the Congo declared an outbreak…
-
U.S. case of Human avian influenza A(H5) virus reported
On Apr. 28, 2022, Centers for Disease Control and Prevention (CDC) reported that a person had tested positive…
-
Stanford University launched $75 million brain disease initiative
On Apr. 26, 2022, Stanford University announced it was awarded a $75 million gift from Nike co-founder Phil…
-
Human Avian H3N8 infection confirmed in Henan province
On Apr. 26, 2022, China’s National Health Commission reported a case of human infection with H3N8 avian influenza…
-
WHO recommended Paxlovid for high-risk COVID patients
On Apr. 22, 2022, the World Health Organization (WHO) made a strong recommendation for nirmatrelvir and ritonavir, sold…
-
Cocrystal Pharma collaborated with the NIAID to evaluate COVID-19 protease inhibitors
On Apr. 21, 2022, Cocrystal Pharma announced a Non-Clinical Evaluation Agreement with the National Institute of Allergy and…
-
Tonix Pharm announced results of retrospective observational database study in over 50,000 long COVID patients
On Apr. 20, 2022, Tonix Pharmaceuticals announced the results of a retrospective observational database study in over 50,000…
-
Regeneron antibody cocktail approved by European Commission to treat and prevent COVID-19
On Nov. 12, 2021, Regeneron announced that the U.S. Food and Drug Administration had extended by three months…
-
Merck announced FDA granted breakthrough therapy designation for V116, investigational 21-valent pneumococcal conjugate vaccine, for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults
On Apr. 14, 2022, Merck announced that V116, the companyﾒs investigational 21-valent pneumococcal conjugate vaccine, had received Breakthrough…
